Takara Bio

Kusatsu, Shiga Prefecture, Japan
Find alternatives to Takara Bio for CAR-T →
8 confirmed programs · 4 sponsors · Last scored 2026-10-29
57.9
Signal Score
○ FDA Inspections ✓ Clinical Trials (8) ○ SEC Filings ✓ Press (18) ○ EMA GMP ○ MHRA GMP

Quick Facts: Takara Bio

Signal Score
57.9/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Kusatsu, Shiga Prefecture, Japan
Modalities
CAR-T, Lentiviral
Active Programs
8 confirmed from ClinicalTrials.gov across 4 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Takara Bio

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 56.2
8 active programs across 4 sponsors
Modalities: CAR-T, Lentiviral
5 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
8 active programs across 4 sponsors · Modalities: CAR-T, Lentiviral · 5 programs in advanced phases (Phase 2/3)
Programs 8
Sponsors4
ModalitiesCAR-T, Lentiviral
8 active programs across 4 sponsors
Modalities: CAR-T, Lentiviral
5 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
NCT07174427 Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel;... PHASE3 Recruiting
NCT05963217 Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen... PHASE1 Recruiting
NCT03250325 Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced... PHASE1/PHASE2 Completed
NCT03155191 Study of TBI-1501 for Relapsed or Refractory Acute... PHASE1/PHASE2 Active Not Recruiting
NCT02418598 AADC Gene Therapy for Parkinson's Disease PHASE1/PHASE2 Terminated
NCT02366546 Investigator Initiated Phase 1 Study of TBI-1301 PHASE1 Unknown
NCT02134262 Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR... PHASE1/PHASE2 Unknown
NCT02096614 Investigator Initiated Phase 1 Study of TBI-1201 PHASE1 Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 manufacturing site: Shiga, JP
Modalities: CAR-T, Lentiviral
Capacity assessment: 58.0/100
Sites: Shiga, JP
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals18 articles (not scored)
1 manufacturing site: Shiga, JP
Modalities: CAR-T, Lentiviral
Capacity assessment: 58.0/100

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Company Signals 18 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-10-24
Takara Bio and SPT Labtech Automate NGS Library Prep - Technology Networks
Takara Bio and SPT Labtech Automate NGS Library Prep  Technology Networks
general 2026-10-21
Takara Bio USA and SPT Labtech Partner to Deliver Automated NGS Workflows - Head Topics
Takara Bio USA and SPT Labtech Partner to Deliver Automated NGS Workflows  Head Topics
general 2026-05-04
AI in Plasmid DNA Manufacturing Market Is Going to Boom| Roche, Takara Bio, Agilent Technologies - openPR.com
AI in Plasmid DNA Manufacturing Market Is Going to Boom| Roche, Takara Bio, Agilent Technologies  openPR.com
regulatory 2026-04-24
Takara Bio, Resistomap join forces to streamline AMR surveillance from environmental samples - Indian Pharma Post
Takara Bio, Resistomap join forces to streamline AMR surveillance from environmental samples  Indian Pharma Post
general 2026-04-20
Takara Bio USA, Inc. Validates New Class of Spatial Technology with Benchmark Study for Cancer Research - BioSpace
Takara Bio USA, Inc. Validates New Class of Spatial Technology with Benchmark Study for Cancer Research  BioSpace
general 2026-04-19
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth  AD HOC NEWS
general 2026-04-19
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth  AD HOC NEWS
regulatory 2026-04-19
Takara Bio and Resistomap forge deal to speed up global fight against superbugs - Indian Pharma Post
Takara Bio and Resistomap forge deal to speed up global fight against superbugs  Indian Pharma Post
general 2026-04-17
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and Single-Cell Technologies - BioSpace
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and Single-Cell Technologies  BioSpace
general 2026-04-16
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and S - PharmiWeb.com
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and S  PharmiWeb.com
general 2026-04-15
Takara Bio Inc stock (JP3463000004): Is biotech gene editing strength enough to drive U.S. investor - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech gene editing strength enough to drive U.S. investor  AD HOC NEWS
general 2026-04-14
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside? - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside?  AD HOC NEWS
general 2026-04-14
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside? - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside?  AD HOC NEWS
general 2026-03-31
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation - BioSpace
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation  BioSpace
general 2026-03-30
Takara Bio USA and Hamilton Partner for Automated NGS Library Prep - San Jose Today - National Today
Takara Bio USA and Hamilton Partner for Automated NGS Library Prep  National Today
general 2026-03-30
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation - Business Wire
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation  Business Wire
general 2026-03-27
TAKARA BIO PB Ratio: 1.36 — 56% Below Median - gurufocus.com
TAKARA BIO PB Ratio: 1.36 — 56% Below Median  gurufocus.com
partnership 2026-02-26
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - BioSpace
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026  BioSpace

Frequently Asked Questions About Takara Bio

How many clinical programs is Takara Bio linked to?
Takara Bio is associated with 8 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Takara Bio's CDMO Signal Score?
Takara Bio has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.
Evaluating Takara Bio for a manufacturing program?
Use the free AI matchmaker to compare Takara Bio against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Lentiviral CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
OmniaBio
Hamilton, ON
Signal Score: 61.5
AAV, Lentiviral, CAR-T, Cell Therapy
ElevateBio BaseCamp
Waltham, MA
Signal Score: 59.0
AAV, Lentiviral, CAR-T

Compare Takara Bio with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Takara Bio
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.